Evidence mapPaperPMID 42058906Full record

ArticleiScience2026

AMPK-p38 axis converts human pluripotent stem cells to naive state.

Zhennan Yang, Yajing Liu, Huaigeng Xu, Junko Yamane, Akitsu Hotta, Wataru Fujibuchi, Jun K Yamashita

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhennan YangDepartment of Cellular and Tissue Communications, Graduate School of Medicine, the University of Tokyo, Tokyo 113-8655, Japan.
Yajing LiuThe Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
Huaigeng XuThe Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
Junko YamaneThe Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
Akitsu HottaThe Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
Wataru FujibuchiDepartment of Cellular and Tissue Communications, Graduate School of Medicine, the University of Tokyo, Tokyo 113-8655, Japan.
Jun K YamashitaDepartment of Cellular and Tissue Communications, Graduate School of Medicine, the University of Tokyo, Tokyo 113-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pluripotent stem cells (PSCs) exist in either a "primed" state or a "naive" state. While several protocols are available to convert primed human PSCs (hPSCs) to the naive-state hPSCs, they often require multiple exogenous factors. Here, we show that the activation of AMP-activated protein kinase (AMPK) or its downstream p38 alone induces naive conversion. Primed hPSCs cultured with activated AMPK-p38 displayed key naive features, including naive marker expression, three-germ-layer differentiation, epigenomic resetting, and increased mitochondrial activity. An AMPK activator-5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR)-synergistically enhances the naive conversion efficiency of reported conversion protocols. Single-cell RNA sequencing (scRNA-seq) with RNA velocity analyses and Totem trajectory mapping identified an intermediate state bridging the primed and naive states. These cells showed three upregulated gene groups: (1) pluripotency genes (e.g.,

Indexed as

cell biologydevelopmental biologystem cells research

Identifiers

PMID42058906
PMCPMC13122662

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.